• IX Biopharma posted a net loss attributable to equity holders of SGD 916,000 for 3Q ended March 31, narrowing 58% year on year, while revenue fell 13% to SGD 1.59 million.
• Gross margin rose 11 percentage points to 38%, while loss before income tax narrowed 58% to SGD 915,000.
• For the nine months ended March 31, net loss narrowed 65% to SGD 2.97 million as revenue slipped 14% to SGD 4.76 million.
• Cash and cash equivalents climbed to SGD 16.49 million at March 31 from SGD 866,000 at June 30, following private placements and warrant exercises that injected SGD 21.25 million into equity.
• Company highlighted a US$40.95 million Department of Defense contract awarded in February 2026 to fund R&D of Wafermine, including Phase 3 development and proposed Emergency Use Authorization purchases.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IX Biopharma Ltd. published the original content used to generate this news brief via Singapore Exchange Limited (SGX) (Ref. ID: E4SII570ZA7PMUBF) on May 08, 2026, and is solely responsible for the information contained therein.